The FDA has approved Foundayo, an oral weight-loss medication from Eli Lilly, marking the second pill-form GLP-1 drug to reach the U.S. market. The once-daily tablet, which contains the active ingredient orforglipron, received clearance this week.
The approval comes roughly two months after Novo Nordisk's Wegovy pill won FDA authorization in December. Both medications represent a significant shift in how GLP-1 drugs—a class of medications originally developed for diabetes—are being delivered to patients seeking weight-loss treatment.
Until recently, GLP-1 drugs were available primarily as weekly injections, a delivery method that limited their appeal to some patients due to needle anxiety or inconvenience. The emergence of oral formulations addresses a practical barrier that may expand the potential market for these increasingly popular weight-loss treatments.
Eli Lilly, based in Indianapolis, has positioned itself as a major player in the weight-loss medication space, competing directly with Novo Nordisk in a market that has seen explosive growth. The company's injectable GLP-1 drug, Mounjaro, has also gained significant traction since its approval.
The arrival of Foundayo gives patients and healthcare providers additional options as demand for weight-loss medications continues to climb. The once-daily dosing schedule may appeal to patients seeking simpler treatment regimens compared to weekly injection schedules.
The approval underscores the FDA's recent focus on expanding access to weight-loss treatments through different delivery mechanisms, reflecting growing recognition of obesity as a treatable medical condition rather than simply a lifestyle issue.
Comments